Transgene’s Board of Directors to gain two new members

Marie Landel and Maya Said nominated as Independent Members of Transgene’s Board of Directors

Transgene, a company that designs and develops viral-based immunotherapies, has proposed two new independent Board members, Marie Landel and Maya Said.

The notice also proposes resolutions on the renewal of the mandates of current Board members Philippe Archinard, Benoit Habert, Alain Merieux, Dominique Takizawa (representing TSGH).

Marie Landel

Marie Landel founded Marie Landel and Associates, now Axcelia Partners, a consultancy based in Cambridge (Massachusetts) specialised in advising European companies on the creation and development of US subsidiaries.

Landel has significant experience supporting French and European biotechnology companies in the United States. In her 27 years of practice, she has built an extensive network in the financial community focused on this sector. Landel is a French CPA (Expert-comptable) and she holds an MBA from the European Business School (Paris, Frankfurt and London).

Landel also sits on the Boards of TxCell, Safe Orthopaedics and Cellnovo. She was also a Foreign Trade Advisor to the French government for 10 years.

Maya Said

Maya Said brings more than 15 years of international strategic, operational and research experience working across academia and the healthcare industry.

Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis and Vice President, Head of Strategy, Science Policy and External Innovation, Global R and D at Sanofi.

Her career started within the HealthCare and Strategy practice of The Boston Consulting Group (BCG).

Said has a PhD in Electrical Engineering, Computer Science and Systems Biology from the Massachusetts Institute of Technology (MIT), as well as two Masters degrees in Electrical Engineering and Computer Science and in Biology. She has also studied finance and healthcare organisational systems at the Harvard Business School.

Said is the author of more than 20 publications in refereed journals such as Nature and PNAS.

Philippe Archinard, Chair and Chief Executive Officer of Transgene, said: “Marie Landel and Maya Saids' appointments will strengthen our international networks, particularly in the US.”